AJP - Lung AJP: Lung Cellular and Molecular Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Lung Cell Mol Physiol 293: L303-L304, 2007. First published June 22, 2007; doi:10.1152/ajplung.00226.2007
1040-0605/07 $8.00
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/2/L303    most recent
00226.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Homer, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Homer, R. J.

EDITORIAL FOCUS

Airway remodeling and RELM-beta

Robert J. Homer

Yale University School of Medicine, New Haven, Connecticut

TYPE 2 INFLAMMATORY RESPONSES are characterized by differentiated CD4+ T helper type 2 (Th2) cells that secrete a panel of cytokines including IL-4, IL-5, IL-9, and IL-13 with the recruitment of multiple effector cells, including B cells producing IgE, mast cells, eosinophils, and basophils. Although inflammation per se attracts a great deal of attention, it is the effects of inflammation on tissue that actually induce disease. Recent gene profiling studies in murine model systems have identified a number of novel molecules that are highly upregulated during type 2 inflammation and that may be involved in tissue injury (21). Among these are members of the resistin-like molecules/found in inflammatory zone (RELM/FIZZ) family that includes RELM-{alpha}/FIZZ1, RELM-beta/FIZZ2, and RELM-{gamma}, all of which share sequence homology to resistin, an adipocyte-secreted factor that can regulate responsiveness to insulin (6, 16). All RELM proteins are secreted, contain highly conserved COOH-terminal cysteine residues, and are expressed during type 2 inflammation (15). Although a RELM-{alpha} ortholog has not been identified in the human genome, human resistin shows a greater similarity in expression pattern to murine RELM-{alpha} than murine resistin and is expressed by leukocytes and myeloid cells. Thus the putative functions for murine RELM-{alpha} may be shared with resistin in humans (20).

The best-studied member of this family is RELM-{alpha}/FIZZ1, which is expressed in the lung and gastrointestinal (GI) tract in pulmonary epithelial cells, dendritic cells, B cells, macrophages, and GI tract goblet cells under a variety of conditions, including parasite infection, Th2 inflammation, and pulmonary fibrosis (15). Expression of RELM-{alpha} is a defining feature of murine alternatively activated macrophages along with expression of arginase and Ym1 (3). RELM-{alpha} is also upregulated in a STAT6-dependent fashion in the alveolar epithelium during allergic and fibrotic conditions. In both cases, it may mediate fibrosis through induction of myofibroblast differentiation, proliferation, and protection from apoptosis (2, 6, 10, 11, 14, 17, 21). Hypoxia upregulates RELM-{alpha} in the lung where it has mitogenic activity for smooth muscle and epithelium (9, 18). RELM-{alpha} has angiogenic activity, which is at least partly mediated through VEGF and VEGFR2 (19). Finally, RELM-{alpha} has been shown to have activity against nerve growth factor-induced neural survival as well (6). Thus RELM-{alpha} is a multipotent molecule involved in multiple aspects of tissue remodeling.

RELM-beta has similar properties in that it is induced in a Th2 cytokine-dependent manner in the lung and GI tract. In the GI tract, RELM-beta has a more restricted expression pattern than RELM-{alpha} in that it is uniquely expressed by goblet cells and requires IL-13 for expression (1). In the context of GI parasite infection, worm expulsion correlates with RELM-beta expression (1, 15). RELM-beta is also upregulated during bacterial colonization of the gut, suggesting a broader function in response to diverse microorganisms in the GI tract (4). RELM-beta is important for maintenance of GI barrier function, but paradoxically the absence of RELM-beta also protects against dextran sulfate-induced colitis (5, 12).

The authors of the companion article had previously shown that RELM-beta was upregulated in a murine asthma model (21). The companion article (13) confirmed that result by Northern blot analysis and quantitative RT-PCR. Expression was primarily limited to airway epithelium and inflammatory cells. IL-4 and IL-13 themselves were each shown to directly induce RELM-beta via a STAT6-dependent pathway. This is not a trivial point, since although STAT6 is the best known signal transduction mediator for IL-4/IL-13, IL-13 also signals through the mitogen-activated protein kinase pathway (8). In allergic models, the induction of RELM-beta was dependent on IL-13, STAT6, and IL-4R{alpha} as shown in the respective gene-deficient mice and as previously reported for STAT6 (17). This is consistent with previous work by the authors who previously reported that most, but not all, gene products in various allergic models (including RELM-beta) were STAT6 dependent (21).

RELM-beta, when directly delivered to the mouse lung, increased the number of macrophages. Direct administration of RELM-beta was also able to directly induce fibrosis and a slight increase in mucus production. In addition to being sufficient to produce fibrosis, RELM-beta was necessary for fibrosis since mice deficient in RELM-beta were protected from airway fibrosis despite equivalent numbers of eosinophils induced. Consistent with the minor effect of RELM-beta on induction of mucus, the absence of RELM-beta had a minor effect on reduction of mucus. In vitro, whereas RELM-beta had no effect on fibroblast mitogenesis, it did enhance fibroblast migration.

What are the future directions we can expect from this work? There is expression of RELM-beta in epithelial cells, but we do not know which cell type, especially in relation to other secondary mediators induced by Th2 inflammation, including RELM-{alpha}. For comparison, chitinases are another family of Th2-induced mediators with some similar properties to the RELM family (15). Different chitinase family members, despite being expressed by "airway epithelium," are actually expressed in mutually exclusive cells that reflect different microanatomic regions of the lung (7). Given the exclusive expression of RELM-beta in goblet cells in the GI tract, this is particularly important to asthma in which goblet cell metaplasia is prominent. It will be important to determine exactly at what step (Th2 induction or response to Th2 mediators) the defect in RELM-beta production lies in the IL-13-, IL-4R{alpha}-, and STAT6-deficient mice. With respect to the direct administration of RELM-beta, the mechanism of fibrosis and inflammation induced by RELM-beta needs to be worked out. RELM-beta has previously been shown to activate peritoneal macrophages to produce TNF-{alpha} and IL-15, thus it is would be particularly important to know if the pulmonary macrophages induced by RELM-beta also show evidence for activation (12). It would also be of interest to determine the relationship of Th2 cytokines, including transforming growth factor-beta, to RELM-beta-induced fibrosis. The result with the RELM-beta-deficient mice is somewhat difficult to interpret since there is little known about the effect of RELM-beta on the development of a Th2 response. At baseline, these mice are not grossly immunologically abnormal, and we are told that there are equivalent numbers of eosinophils upon allergen challenge (5, 13). However, it will be important to formally exclude a role of RELM-beta on the Th2 response. Finally, in addition to fibrosis, it would be of interest to look for effects of RELM-beta on other aspects of airway remodeling, such as effects on smooth muscle or vascularity.

Despite these areas of uncertainty, RELM-beta potentially appears to belong to a family of mediators that may be downstream of the immune response and both amplify the inflammatory response and mediate some of its effects. The ability to produce fibrosis is particularly intriguing. All in all, these data implicate RELM-beta as a mediator dependent on Th2 responses that is also implicated in airway remodeling.


    FOOTNOTES
 

Address for reprint requests and other correspondence: R. J. Homer, Yale Univ. School of Medicine, 310 Cedar St., PO Box 208023, New Haven, CT 06520-8023 (e-mail: Robert.Homer{at}yale.edu)


    REFERENCES
 TOP
 REFERENCES
 

  1. Artis D, Wang ML, Keilbaugh SA, He W, Brenes M, Swain GP, Knight PA, Donaldson DD, Lazar MA, Miller HR, Schad GA, Scott P, Wu GD. RELMbeta/FIZZ2 is a goblet cell-specific immune-effector molecule in the gastrointestinal tract. Proc Natl Acad Sci USA 101: 13596–13600, 2004.[Abstract/Free Full Text]
  2. Chung M, Liu T, Ullenbruch M, Phan S. Antiapoptotic effect of found in inflammatory zone (FIZZ)1 on mouse lung fibroblasts. J Pathol 212: 180–187, 2007.[CrossRef][Medline]
  3. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 3: 23–35, 2003.[CrossRef][Web of Science][Medline]
  4. He W, Wang ML, Jiang HQ, Steppan CM, Shin ME, Thurnheer MC, Cebra JJ, Lazar MA, Wu GD. Bacterial colonization leads to the colonic secretion of RELMbeta/FIZZ2, a novel goblet cell-specific protein. Gastroenterology 125: 1388–1397, 2003.[CrossRef][Web of Science][Medline]
  5. Hogan SP, Seidu L, Blanchard C, Groschwitz K, Mishra A, Karow ML, Ahrens R, Artis D, Murphy AJ, Valenzuela DM, Yancopoulos GD, Rothenberg ME. Resistin-like molecule beta regulates innate colonic function: barrier integrity and inflammation susceptibility. J Allergy Clin Immunol 118: 257–268, 2006.[CrossRef][Web of Science][Medline]
  6. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, Frantz GD, Tumas DB, Peale FVJ, Shelton DL, Hebert CC. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 19: 4046–4055, 2000.[CrossRef][Web of Science][Medline]
  7. Homer RJ, Zhu Z, Cohn L, Lee CG, White WI, Chen S, Elias JA. Differential expression of chitinases identify subsets of murine airway epithelial cells in allergic inflammation. Am J Physiol Lung Cell Mol Physiol 291: L502–L511, 2006.[Abstract/Free Full Text]
  8. Lee PJ, Zhang X, Shan P, Ma B, Lee CG, Homer RJ, Zhu Z, Rincon M, Mossman BT, Elias JA. ERK1/2 mitogen-activated protein kinase selectively mediates IL-13-induced lung inflammation and remodeling in vivo. J Clin Invest 116: 163–173, 2006.[CrossRef][Web of Science][Medline]
  9. Li D, Fernandez LG, Dodd-o J, Langer J, Wang D, Laubach VE. Upregulation of hypoxia-induced mitogenic factor in compensatory lung growth after pneumonectomy. Am J Respir Cell Mol Biol 32: 185–191, 2005.[Abstract/Free Full Text]
  10. Liu T, Dhanasekaran SM, Jin H, Hu B, Tomlins SA, Chinnaiyan AM, Phan SH. FIZZ1 stimulation of myofibroblast differentiation. Am J Pathol 164: 1315–1326, 2004.[Abstract/Free Full Text]
  11. Liu T, Jin H, Ullenbruch M, Hu B, Hashimoto N, Moore B, McKenzie A, Lukacs NW, Phan SH. Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6. J Immunol 173: 3425–3431, 2004.[Abstract/Free Full Text]
  12. McVay LD, Keilbaugh SA, Wong TM, Kierstein S, Shin ME, Lehrke M, Lefterova MI, Shifflett DE, Barnes SL, Cominelli F, Cohn SM, Hecht G, Lazar MA, Haczku A, Wu GD. Absence of bacterially induced RELMbeta reduces injury in the dextran sodium sulfate model of colitis. J Clin Invest 116: 2914–2923, 2006.[CrossRef][Web of Science][Medline]
  13. Mishra A, Wang M, Schlotman J, Nikolaidis NM, DeBrosse CW, Karow ML, Rothenberg ME. Resistin-like molecule-beta is an allergen-induced cytokine with inflammatory and remodeling activity in the murine lung. Am J Physiol Lung Cell Mol Physiol June 1, 2007; doi:10.1152/ajplung.00147.2007.
  14. Mora AL, Torres-Gonzalez E, Rojas M, Corredor C, Ritzenthaler J, Xu J, Roman J, Brigham K, Stecenko A. Activation of alveolar macrophages via the alternative pathway in herpesvirus-induced lung fibrosis. Am J Respir Cell Mol Biol 35: 466–473, 2006.[Abstract/Free Full Text]
  15. Nair MG, Guild KJ, Artis D. Novel effector molecules in type 2 inflammation: lessons drawn from helminth infection and allergy. J Immunol 177: 1393–1399, 2006.[Free Full Text]
  16. Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, Enders GH, Silberg DG, Wen X, Wu GD, Lazar MA. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 98: 502–506, 2001.[Abstract/Free Full Text]
  17. Stutz AM, Pickart LA, Trifilieff A, Baumruker T, Prieschl-Strassmayr E, Woisetschlager M. The Th2 cell cytokines IL-4 and IL-13 regulate found in inflammatory zone 1/resistin-like molecule alpha gene expression by a STAT6 and CCAAT/enhancer-binding protein-dependent mechanism. J Immunol 170: 1789–1796, 2003.[Abstract/Free Full Text]
  18. Teng X, Li D, Champion HC, Johns RA. FIZZ1/RELMalpha, a novel hypoxia-induced mitogenic factor in lung with vasoconstrictive and angiogenic properties. Circ Res 92: 1065–1067, 2003.[Abstract/Free Full Text]
  19. Yamaji-Kegan K, Su Q, Angelini DJ, Champion HC, Johns RA. Hypoxia-induced mitogenic factor has proangiogenic and proinflammatory effects in the lung via VEGF and VEGF receptor-2. Am J Physiol Lung Cell Mol Physiol 291: L1159–L1168, 2006.[Abstract/Free Full Text]
  20. Yang RZ, Huang Q, Xu A, McLenithan JC, Eisen JA, Shuldiner AR, Alkan S, Gong DW. Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun 310: 927–935, 2003.[CrossRef][Web of Science][Medline]
  21. Zimmermann N, Mishra A, King NE, Fulkerson PC, Doepker MP, Nikolaidis NM, Kindinger LE, Moulton EA, Aronow BJ, Rothenberg ME. Transcript signatures in experimental asthma: identification of STAT6-dependent and -independent pathways. J Immunol 172: 1815–1824, 2004.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/2/L303    most recent
00226.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Homer, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Homer, R. J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.